pancreatic cancer pancreatic ductal adenocarcinoma
Conditions
Interventions
Investigational treatment consist of oral micellar curcumin (Espera®).
Resectable patients will receive 2dd2 capsules (18 mg micellar
curcumin/capsule) for a period of at least 2 weeks prior to thei
Sponsors
Stichting Leveronderzoek
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Age * 18 years. * Diagnosed with resectable or borderline resectable pancreatic cancer (patientgroup 1) OR stable (metastatic)disease after standard of care treatment (patientgroup 2). * An SIII of 900 or higher. * Bilirubin
Exclusion criteria
Exclusion criteria: * Prior radiotherapy, chemotherapy, or resection for pancreatic cancer if included in patientgroup 1. * Previous malignancy (excluding non-melanoma skin cancer), unless no evidence of disease and diagnosed more than 2 years before diagnosis of pancreatic cancer. * Pregnancy. * Unable to draw blood for study purposes. * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine whether micellar curcumin (Espera®) is able to improve the SIII index in operable PDAC patients OR PDAC patients with stable (metastatic) disease after standard of care treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| There will be no secondary objective for patient group 1: (borderline) resectable pancreatic cancer patients. For patient group 2: pancreatic cancer patients with stable (metastatic) disease after standard of care we will determine if there is a time-trend in SIII changes by using repeated measurements. | — |
Countries
Netherlands
Outcome results
None listed